Sonoma Pharma Launches New Urinary Tract Infection Product In New Zealand, Australia, South Africa
Sonoma Pharmaceuticals Inc (NASDAQ: SNOA) has launched Microdox, an urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa.
Microdox is a super-oxidized solution based on Sonoma's patented Microcyn Technology intended to treat and prevent infections in the urinary tract and bladder.
Microdox is a non-irritating and non-toxic solution and is ready for immediate use. It is currently available through Sonoma's partners, Te Arai BioFarma in New Zealand and Australia, and NuAngle in South Africa.
Also See: Sonoma Pharma Expands Its Partner Network For Oral, Dental Products In US & China.
"We believe Microdox is a unique bladder irrigation that fulfills the requirements of an effective adjunct UTI prevention and treatment for removing UTI-causing bacteria, bacterial biofilms, and drug-resistant strains," said Scott Lissington, COO of Te Arai BioFarma.
Price Action: SNOA shares are up 8.33% at $3.64 during the market session on the last check Wednesday.
See more from Benzinga
Health Canada Approves NanoVibronix's PainGuard, UroGuard As Licensed Devices
Adagio's COVID-19 Antibody Meets Primary Goals Across Pre & Post-Exposure Prophylaxis, Treatment
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.